This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
by Zacks Equity Research
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
ALNYPositive Net Change ANIPNegative Net Change VTRSNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
NVONegative Net Change LLYPositive Net Change OMERNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
NVSNegative Net Change BAYRYPositive Net Change TVTXNegative Net Change
biotechnology medical pharmaceuticals
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs gene-therapy pharmaceuticals
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
ALNYPositive Net Change BCRXNegative Net Change CRMDNegative Net Change ATXSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Brookfield Infrastructure Partners (BIP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BIPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
by Ekta Bagri
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
ALNYPositive Net Change ALLONegative Net Change CMMBNegative Net Change TVRDNegative Net Change
biotechnology biotechs medical pharmaceuticals
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
by Zacks Equity Research
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
BIIBPositive Net Change FOLDNegative Net Change CRMDNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
ADCTNo Net Change ZTSNegative Net Change ALLONegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs gene-therapy pharmaceuticals
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
by Ekta Bagri
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
NVSNegative Net Change BMYNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Oct 13, 2025
by Zacks Equity Research
Companies In The News Are: LEVI, APLD, QCOM, AZN.
AZNPositive Net Change QCOMNegative Net Change APLDNegative Net Change LEVINegative Net Change
biotechnology finance retail semiconductor
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
by Zacks Equity Research
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
OVIDNegative Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
FuelCell Energy (FCEL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
FCELNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
A-Mark Precious Metals (AMRK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AMRKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
by Ahan Chakraborty
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Growth Stocks to Strengthen Your Portfolio in Q4 After a Fabulous Q3
by Nalak Das
After a stellar Q3 for Wall Street, five growth picks - MU, WDAY, EXAS, EVR, and CDE - stand out with rising earnings estimates.
MUNegative Net Change EVRNegative Net Change WDAYNegative Net Change CDENegative Net Change EXASNegative Net Change
basic-materials biotechnology finance internet semiconductor
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJPositive Net Change BAYRYPositive Net Change FOLDNegative Net Change SPRONegative Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALANegative Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals